Bio-Rad Laboratories, Inc.Class A (BIO)

From the record

Bio-Rad Laboratories, Inc.Class A's filings since 2017 show 4 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2019-03-25); a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2019-03-04) (its current reports).

From the record

Bio-Rad Laboratories, Inc.Class A's 10 filed years say what it did: revenue went from $2.1 billion in fiscal 2016 to $2.6 billion in fiscal 2025, up 2.5% a year; it rose in 6 of 9 years; the deepest fall was 12% from fiscal 2021 to fiscal 2024; net income was positive in 7 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Bio-Rad Laboratories, Inc.Class A's diluted share count shrank about 2.9% a year, and dividends and buybacks returned about 68% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 4 sales and 0 purchases of their own stock on the open market in the year to 2026-11-12 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Bio-Rad Laboratories, Inc.Class A earned about 10 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 13 cents per dollar of everything the company owns. Leverage: it owed about 30 cents per dollar of assets, and net share issuance: its share count shrank 3.3% over the year (the filed statements).

From the record

Bio-Rad Laboratories, Inc.Class A's standing among 21 graded names in its industry family: revenue of $2.6 billion in fiscal 2025 ranks in the top 36% by size; a net margin of 29.4% ranks in the top 2%; revenue growth of -2.7% a year over the last 3 filed years ranks in the bottom 28% (its annual reports).

From the record

Bio-Rad Laboratories, Inc.Class A's leadership, from its insiders' filings and its current reports: the chief executive on the record is Schwartz, Norman D (Chairman & CEO, as filed), filing under that title since 2006-04-05, 20.6 years (top 8% of its family); the 14 officers and directors filing in the last fifteen months have been on the record a median of 3.3 years (bottom 31%); 8 officer or director changes were reported on Form 8-K since 2023-11-13, against the 14 people in charge now (bottom 43%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Bio-Rad Laboratories, Inc.Class A's room to grow, from the newest filed statements (fiscal 2025): cash of $530 million against debt of $1.2 billion leaves -6.4% of its assets as net cash, bottom 34% of its family; cash from operations less capital spending is 14.5% of revenue (top 31%); a gross margin of 51.9% (top 36%); research spending of 10.7% of revenue (bottom 33%) (its annual report).

From the record

Bio-Rad Laboratories, Inc.Class A's growth drivers, from the filed years to fiscal 2025: revenue grew -2.7% a year over the last three filed years against 2.5% over all 10, slowing (top 42% of its family); the newest year grew 0.7% (bottom 40%); research spending grew 2.4% a year (top 37%); capital spending grew 11.8% a year (top 17%) (its annual reports). Bio-Rad Laboratories, Inc.Class A reported 2 lines of business in fiscal 2025: Clinical Diagnostics at $1.6 billion (61%), Life Science at $1.0 billion (40%); 1 of 2 grew against the year before (its annual report).

From the record

Bio-Rad Laboratories, Inc.Class A's newest year against its own record: revenue of $2.6 billion in fiscal 2025 came in 5.2% above the $2.5 billion its prior three years' pace pointed to (top 22% of its family); net income of $760 million against a prior three-year average of $2.0 billion (top 7%); a net margin of 29.4% against -75.1% before (top 22%) (its annual reports).